BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 1976136)

  • 1. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
    J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
    Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
    Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
    Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes.
    Mestdagh N; Pommery N; Saucier JM; Hecquet B; Fournier C; Slomianny C; Teissier E; Hénichart JP
    Anticancer Res; 1994; 14(3A):869-74. PubMed ID: 7915509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
    Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
    Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
    Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
    J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
    Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
    Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
    Slovak ML; Hoeltge GA; Dalton WS; Trent JM
    Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
    Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
    Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.